Deivide DE Sousa Oliveira, Flávia Melo Cunha DE Pinho Pessoa, Isadora Lima Pontes, Kaira Mara DE Albuquerque Cordeiro, Beatriz Maria Dias Nogueira, Guilherme Passos DE Morais, Rodrigo Monteiro Ribeiro, Fabiana Aguiar Carneiro Silva, Lívia Andrade Gurgel, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes
{"title":"抗微生物药物耐药性和细胞遗传风险对急性髓性白血病死亡率的协同作用。","authors":"Deivide DE Sousa Oliveira, Flávia Melo Cunha DE Pinho Pessoa, Isadora Lima Pontes, Kaira Mara DE Albuquerque Cordeiro, Beatriz Maria Dias Nogueira, Guilherme Passos DE Morais, Rodrigo Monteiro Ribeiro, Fabiana Aguiar Carneiro Silva, Lívia Andrade Gurgel, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes","doi":"10.21873/anticanres.17690","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Acute myeloid leukemia (AML) is an aggressive hematological malignancy requiring intensive chemotherapy, which induces profound immunosuppression. Multidrug-resistant Gram-negative (MDRGN) bacterial colonization and infection are an emerging challenge in AML management, potentially worsening survival outcomes. This retrospective single-center cohort study evaluated the impact of MDRGN colonization and infection on overall survival (OS) in patients with AML undergoing chemotherapy.</p><p><strong>Materials and methods: </strong>MDRGN status was determined <i>via</i> routine cultures, while infection was defined by positive sterile-site cultures accompanied by clinical symptoms. Cytogenetic risk was stratified according to ELN 2022 criteria. Survival analysis was performed using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 64 patients with AML were analyzed, with a median OS of 8.03 months. MDRGN-colonized patients had significantly shorter OS (3.53 months) than non-colonized patients (18.83 months; <i>p</i>=0.024). High-risk cytogenetics independently reduced OS (4.63 <i>vs.</i> 18.93 months; <i>p</i>=0.011). Patients with both high-risk cytogenetics and MDRGN colonization had the poorest prognosis, with a median OS of 1.47 months. MDRGN colonization was associated with significantly increased infection risk, treatment-related complications, and reduced survival in AML. The combined effect of antimicrobial resistance and high-risk cytogenetics suggests a synergistic impact on prognosis. Delayed targeted antibiotic therapy, chemotherapy modifications, and increased septic episodes likely contributed to the observed mortality.</p><p><strong>Conclusion: </strong>MDRGN colonization is a critical negative prognostic factor in AML, particularly in patients with adverse cytogenetics. Strengthening infection control measures, implementing rapid molecular diagnostics, and optimizing antimicrobial stewardship are essential to improve outcomes.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3295-3304"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synergistic Effect of Antimicrobial Resistance and Cytogenetic Risk on Mortality in Acute Myeloid Leukemia.\",\"authors\":\"Deivide DE Sousa Oliveira, Flávia Melo Cunha DE Pinho Pessoa, Isadora Lima Pontes, Kaira Mara DE Albuquerque Cordeiro, Beatriz Maria Dias Nogueira, Guilherme Passos DE Morais, Rodrigo Monteiro Ribeiro, Fabiana Aguiar Carneiro Silva, Lívia Andrade Gurgel, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes\",\"doi\":\"10.21873/anticanres.17690\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Acute myeloid leukemia (AML) is an aggressive hematological malignancy requiring intensive chemotherapy, which induces profound immunosuppression. Multidrug-resistant Gram-negative (MDRGN) bacterial colonization and infection are an emerging challenge in AML management, potentially worsening survival outcomes. This retrospective single-center cohort study evaluated the impact of MDRGN colonization and infection on overall survival (OS) in patients with AML undergoing chemotherapy.</p><p><strong>Materials and methods: </strong>MDRGN status was determined <i>via</i> routine cultures, while infection was defined by positive sterile-site cultures accompanied by clinical symptoms. Cytogenetic risk was stratified according to ELN 2022 criteria. Survival analysis was performed using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 64 patients with AML were analyzed, with a median OS of 8.03 months. MDRGN-colonized patients had significantly shorter OS (3.53 months) than non-colonized patients (18.83 months; <i>p</i>=0.024). High-risk cytogenetics independently reduced OS (4.63 <i>vs.</i> 18.93 months; <i>p</i>=0.011). Patients with both high-risk cytogenetics and MDRGN colonization had the poorest prognosis, with a median OS of 1.47 months. MDRGN colonization was associated with significantly increased infection risk, treatment-related complications, and reduced survival in AML. The combined effect of antimicrobial resistance and high-risk cytogenetics suggests a synergistic impact on prognosis. Delayed targeted antibiotic therapy, chemotherapy modifications, and increased septic episodes likely contributed to the observed mortality.</p><p><strong>Conclusion: </strong>MDRGN colonization is a critical negative prognostic factor in AML, particularly in patients with adverse cytogenetics. Strengthening infection control measures, implementing rapid molecular diagnostics, and optimizing antimicrobial stewardship are essential to improve outcomes.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 8\",\"pages\":\"3295-3304\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17690\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17690","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:急性髓性白血病(AML)是一种侵袭性的血液系统恶性肿瘤,需要高强度的化疗,引起严重的免疫抑制。耐多药革兰氏阴性(MDRGN)细菌定植和感染是AML管理中的一个新挑战,可能会恶化生存结果。这项回顾性单中心队列研究评估了MDRGN定植和感染对化疗AML患者总生存期(OS)的影响。材料和方法:通过常规培养确定MDRGN状态,通过无菌区培养阳性伴临床症状确定感染。根据ELN 2022标准对细胞遗传学风险进行分层。采用Kaplan-Meier法进行生存分析。结果:共分析64例AML患者,中位OS为8.03个月。mdrgn定殖患者的OS(3.53个月)明显短于未定殖患者(18.83个月;p = 0.024)。高危细胞遗传学独立降低OS (4.63 vs. 18.93个月;p = 0.011)。同时存在高危细胞遗传学和MDRGN定植的患者预后最差,中位OS为1.47个月。MDRGN定植与AML感染风险显著增加、治疗相关并发症和生存率降低相关。抗菌素耐药性和高危细胞遗传学的联合作用提示对预后有协同影响。延迟靶向抗生素治疗、化疗修改和脓毒症发作增加可能导致观察到的死亡率。结论:MDRGN定植是AML的一个关键的负面预后因素,特别是在细胞遗传学不良的患者中。加强感染控制措施、实施快速分子诊断和优化抗微生物药物管理对改善结果至关重要。
Synergistic Effect of Antimicrobial Resistance and Cytogenetic Risk on Mortality in Acute Myeloid Leukemia.
Background/aim: Acute myeloid leukemia (AML) is an aggressive hematological malignancy requiring intensive chemotherapy, which induces profound immunosuppression. Multidrug-resistant Gram-negative (MDRGN) bacterial colonization and infection are an emerging challenge in AML management, potentially worsening survival outcomes. This retrospective single-center cohort study evaluated the impact of MDRGN colonization and infection on overall survival (OS) in patients with AML undergoing chemotherapy.
Materials and methods: MDRGN status was determined via routine cultures, while infection was defined by positive sterile-site cultures accompanied by clinical symptoms. Cytogenetic risk was stratified according to ELN 2022 criteria. Survival analysis was performed using the Kaplan-Meier method.
Results: A total of 64 patients with AML were analyzed, with a median OS of 8.03 months. MDRGN-colonized patients had significantly shorter OS (3.53 months) than non-colonized patients (18.83 months; p=0.024). High-risk cytogenetics independently reduced OS (4.63 vs. 18.93 months; p=0.011). Patients with both high-risk cytogenetics and MDRGN colonization had the poorest prognosis, with a median OS of 1.47 months. MDRGN colonization was associated with significantly increased infection risk, treatment-related complications, and reduced survival in AML. The combined effect of antimicrobial resistance and high-risk cytogenetics suggests a synergistic impact on prognosis. Delayed targeted antibiotic therapy, chemotherapy modifications, and increased septic episodes likely contributed to the observed mortality.
Conclusion: MDRGN colonization is a critical negative prognostic factor in AML, particularly in patients with adverse cytogenetics. Strengthening infection control measures, implementing rapid molecular diagnostics, and optimizing antimicrobial stewardship are essential to improve outcomes.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.